Ridinilazole: a novel antimicrobial for Clostridium difficile infection

Por Cho, Jonathan C., Crotty, Matthew P., Pardo, Joe
Publicado no Ann Gastroenterol (2019)

New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides

Por Crotty, Matthew P., Krekel, Tamara, Burnham, Carey-Ann D., Ritchie, David J.
Publicado no J Clin Microbiol (2016)

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria

Por Gonzalez, Mark D., McMullen, Allison R., Wallace, Meghan A., Crotty, Matthew P., Ritchie, David J., Burnham, Carey-Ann D.
Publicado no Ann Lab Med (2017)

Learning Experiences Within Infectious Diseases Pharmacy Residency Programs in the United States: A Cross-Sectional Survey

Por Cho, Jonathan C, Crotty, Matthew P, Kufel, Wesley D, Chahine, Elias B, Sofjan, Amelia K, Gallagher, Jason C, Estrada, Sandy J
Publicado no Open Forum Infect Dis (2019)

Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship

Por Crotty, Matthew P., Meyers, Shelby, Hampton, Nicholas, Bledsoe, Stephanie, Ritchie, David J., Buller, Richard S., Storch, Gregory A., Kollef, Marin H., Micek, Scott T.
Publicado no Crit Care (2015)

Epidemiology, Co-Infections, and Outcomes of Viral Pneumonia in Adults: An Observational Cohort Study

Por Crotty, Matthew P., Meyers, Shelby, Hampton, Nicholas, Bledsoe, Stephanie, Ritchie, David J., Buller, Richard S., Storch, Gregory A., Micek, Scott T., Kollef, Marin H.
Publicado no Medicine (Baltimore) (2015)